Reaction
Graft Complication reporting signals
As of the last recalculation, Graft Complication appears in 584 FAERS reports alongside 22 co-occurring drug terms. The strongest observed disproportionality signal is THIOTEPA (PRR 122.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Thiotepa | 31 | 122.1 | 122.5 |
| Basiliximab | 33 | 105.9 | 106.2 |
| Busulfan | 29 | 69.1 | 69.2 |
| Posaconazole Delayed-Release | 20 | 67.2 | 67.3 |
| Fludarabine Phosphate | 53 | 52.7 | 52.8 |
| Posaconazole | 20 | 45.4 | 45.4 |
| Tacrolimus Ointment 0.1% | 124 | 44.8 | 44.8 |
| Tacrolimus Extended-Release Capsules | 124 | 44.7 | 44.7 |
| Tacrolimus | 144 | 43.2 | 43.2 |
| Mycophenolate Mofetil Hydrochloride | 123 | 40.5 | 40.6 |
| Mycophenolate Mofetil | 122 | 40.2 | 40.2 |
| Inclisiran | 8 | 36.0 | 36.1 |
| Mycophenolic Acid | 27 | 31.5 | 31.5 |
| Abacavir Sulfate | 7 | 25.9 | 25.9 |
| Valganciclovir | 13 | 25.1 | 25.1 |
| Valganciclovir Hydrochloride | 13 | 25.1 | 25.1 |
| Ganciclovir | 7 | 24.7 | 24.7 |
| Sirolimus | 9 | 24.2 | 24.2 |
| Ganciclovir Sodium | 7 | 23.8 | 23.9 |
| Mycophenilic Acid | 13 | 22.8 | 22.9 |
| Ifosfamide | 10 | 16.9 | 16.9 |
| Cinacalcet Hydrochloride | 8 | 6.2 | 6.2 |